FDA Continues "Tayloring" Senior Leadership
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO executive VP John Taylor returns to the agency as special counselor while FDA also fills another key liaison slot.
You may also be interested in...
FDA Counselor Taylor Is Acting Deputy As Hamburg Mulls Reorganization
John Taylor, an agency veteran who returned in 2009 after five years in industry, will take over as acting principal deputy commissioner for 60 days following Joshua Sharfstein's departure on Jan. 7.
FDA Counselor Taylor Is Acting Deputy As Hamburg Mulls Reorganization
John Taylor, an agency veteran who returned in 2009 after five years in industry, will take over as acting principal deputy commissioner for 60 days following Joshua Sharfstein's departure on Jan. 7.
Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets